Blood DNA methylation analysis of 10 PAD patients (mean age 72.7 years) versus 22 age-matched controls identified 16,854 high-confidence differentially methylated genes, with hypomethylation predominating. Gene ontology enrichment pointed to muscle system processes, embryonic organ development, calcium and MAPK signaling, cadherin pathways, and cytoskeletal remodeling — programs typically silenced in adult vasculature but reactivated during pathological states like vascular smooth muscle cell phenotypic switching and endothelial dysfunction.
This preprint, posted on medRxiv and not yet peer-reviewed, offers a mechanistically compelling but methodologically constrained snapshot of PAD's epigenetic landscape. The finding that PAD blood epigenomes recapitulate developmental vascular programs aligns with the growing literature on VSMC dedifferentiation as a driver of atherosclerotic plaque instability, and extends it into the epigenetic domain. However, the pilot's critical limitations are substantial: only 10 PAD cases were profiled using pooled DNA — a design that eliminates individual-level variance and prevents standard statistical modeling. Pooled analysis inflates apparent signal and cannot distinguish causal methylation changes from downstream consequences of disease or medication effects common in this age group. The 935,000-CpG platform is robust, but blood-derived methylation may not reflect arterial tissue biology. Despite these constraints, the 16,854 gene intersect provides a hypothesis-generating roadmap for targeted validation in larger, tissue-specific cohorts. Incremental for now, but directionally important if replicated.
